Claims
- 1. An inhalable powder pharmaceutical composition comprising:
(a) a tiotropium salt; (b) an antihistamine; and (c) a pharmaceutically acceptable excipient selected from glucose, arabinose lactose, saccharose or maltose, the tiotropium salt and the antihistamine optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates.
- 2. The inhalable powder pharmaceutical composition according to claim 1, wherein the tiotropium salt is a salt with a counter-ion selected from chloride, bromide, iodide, p-toluene sulfonate, or methylsulfate.
- 3. The inhalable powder pharmaceutical composition of claim 2, wherein the counter-ion is bromide.
- 4. The inhalable powder pharmaceutical composition according to claim 1, wherein the antihistamine is selected from the group consisting of: epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimethindene, clemastine, bamipine, dexchlorpheniramine, pheniramine, doxylamine, chlorphenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratadine, and meclozine.
- 5. The inhalable powder pharmaceutical composition according to claim 2, wherein the antihistamine is selected from the group consisting of: epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimethindene, clemastine, bamipine, dexchlorpheniramine, pheniramine, doxylamine, chlorphenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratadine, and meclozine.
- 6. The inhalable powder pharmaceutical composition according to claim 3, wherein the antihistamine is selected from the group consisting of: epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, mizolastine, ketotifen, emedastine, dimethindene, clemastine, bamipine, dexchlorpheniramine, pheniramine, doxylamine, chlorphenoxamine, dimenhydrinate, diphenhydramine, promethazine, ebastine, desloratadine, and meclozine.
- 7. The inhalable powder pharmaceutical composition according to claim 3, wherein the antihistamine is selected from the group consisting of: epinastine, cetirizine, azelastine, fexofenadine, levocabastine, loratadine, ebastine, desloratadine and mizolastine.
- 8. The inhalable powder pharmaceutical composition according to claim 1, wherein the weight ratios of the tiotropium salt to the antihistamine are in the range of from 1:300 to 50:1.
- 9. The inhalable powder pharmaceutical composition according to claim 8, wherein the weight ratios of the tiotropium salt to the antihistamine are in the range of from 1:250 to 40:1.
- 10-16 (Cancelled)
- 17. A capsule containing an inhalable powder pharmaceutical composition according to claim 1.
- 18. A capsule containing an inhalable powder pharmaceutical composition according to claim 2.
- 19. A capsule containing an inhalable powder pharmaceutical composition according to claim 3.
- 20-23 (Cancelled)
- 24. A capsule containing an inhalable powder pharmaceutical composition according to claim 8.
- 25. A capsule containing an inhalable powder pharmaceutical composition according to claim 9.
- 26-53 (Cancelled)
- 54. A method of treating allergic or non-allergic rhinitis in a patient comprising administering to the patient a therapeutically effective amount of the inhalable powder pharmaceutical composition according to claim 1.
- 55. A kit comprising one or more unit dosage containers comprising an inhalable powder pharmaceutical composition, each unit dosage container comprising:
(a) a tiotropium salt; (b) an antihistamine; and (c) a pharmaceutically acceptable excipient selected from glucose arabinose, lactose saccharose or maltose, the tiotropium salt and the antihistamine optionally in the form of their enantiomers, mixtures of their enantiomers, their racemates, their solvates, or their hydrates.
- 56. The kit according to claim 55, further comprising instructions with directions for using the kit.
- 57-58 (Cancelled)
- 59. The inhalable powder pharmaceutical composition according to claim 1 wherein the tiotropium salt is in the form of a hydrate.
- 60. The inhalable powder according to claim 59 wherein the hydrate form of the tiotropium salt comprises tiotropium bromide monohydrate.
- 61. The inhalable powder pharmaceutical composition according to claim 1 wherein the antihistamine comprises epinastine.
- 62. The inhalable powder pharmaceutical composition according to claim 9 wherein the tiotropium salt is in the form of the monohydrate and the antihistamine comprises epinastine.
- 63. The capsule according to claim 19 wherein the tiotropium salt component of the inhalable powder pharmaceutical composition is in the form of the monohydrate and the antihistamine component comprises epinastine.
- 64. The capsule according to claim 63 wherein the weight ratios of the monohydrate form of the tiotropium salt to the antihistamine comprises 1:250 to 40:1.
- 65. The kit according to claim 55 wherein the tiotropium salt is in the form of the monohydrate and the antihistamine comprises epinastine.
Priority Claims (2)
Number |
Date |
Country |
Kind |
100 54 042.2 |
Oct 2000 |
DE |
|
101 38 272.3 |
Aug 2001 |
DE |
|
RELATED APPLICATIONS
[0001] This application is a continuation of U.S. Ser. No. 10/007,182, filed Oct. 19, 2001, which claims benefit of U.S. Provisional Application Serial No. 60/253,613, filed Nov. 28, 2000, and prior provisional application Serial No. 60/314,599, filed Aug. 24, 2001, which applications are incorporated herein by their entirety.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60253613 |
Nov 2000 |
US |
|
60314599 |
Aug 2001 |
US |
Continuations (1)
|
Number |
Date |
Country |
Parent |
10007182 |
Oct 2001 |
US |
Child |
10824391 |
Apr 2004 |
US |